Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Sara Rossetti, Sidsel Jacobsen Juul, Frank Eriksson, Peder Emil Warming, Charlotte Glinge, Tarec Christoffer Christoffer El-Galaly, Jacob Haaber Christensen, Peter Kamper, Peter de Nully Brown, Maja Maraldo, Jacob Tfelt-Hansen, Martin Hutchings

Blood (2023) 142 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2023-172989

Published: 2023

Journal Articles

Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Rasmus Rask Kragh Jørgensen, Sandra Eloranta, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Soerensen, Peter Kamper, Andrew M Evens, Matthew J. Maurer, Susan K Parsons, Angie Mae Rodday, Jenica Upshaw, Tarec Christoffer Christoffer El-Galaly, Lasse Hjort Jakobsen

Blood (2023) 142 (Supplement 1): 4455.

https://doi.org/10.1182/blood-2023-178498

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Karin Fahl Wader, Ingrid Glimelius

Blood (2022) 140 (Supplement 1): 184–185.

https://doi.org/10.1182/blood-2022-155654

Published: 2022

Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Blood (2022) 140 (Supplement 1): 1464–1466.

https://doi.org/10.1182/blood-2022-158203

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat

Blood (2022) 140 (Supplement 1): 850–851.

https://doi.org/10.1182/blood-2022-158298

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

Arnon P. Kater, Jacob Haaber Christensen, Hans Herluf Bentzen, Carsten Utoft Niemann, Martin Hutchings, Jenny Chen, Marcia Rios, Tammy Palenski, Tommy Li, Anthony R. Mato

Blood (2021) 138 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2021-146563

Published: 2021

Journal Articles

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

David Belada, Jacob Haaber Christensen, Kristina Drott, Sylvia Snauwaert, Joshua Brody, Mayur Narkhede, Fritz Offner, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi, Michael Roost Clausen

Blood (2021) 138 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2021-146569

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Amitkumar Mehta, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane, Guillermo Rodriguez, Michal Taszner, Parameswaran Venugopal, Vittorio Ruggero Zilioli, Fred Zheng, Douglas J DeMarini, Wei Jiang, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 382.

https://doi.org/10.1182/blood-2021-147867

Published: 2021

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Amitkumar Mehta, MD, Marek Trněný, MD, Jan Walewski, MD, Vincent Ribrag, MD, Caroline Dartigeas, MD, Jacob Haaber Christensen, MD PhD, Fabrizio Pane, MD, Guillermo Rodríguez, MD, Michal Taszner, MD, Parameswaran Venugopal, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134872

Published: 2020

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 997.

https://doi.org/10.1182/blood-2018-99-110563

Published: 2018

Journal Articles

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Tove Wästerlid, MD PhD, Jorne Lionel Biccler, MSc, Peter de Nully Brown, MD PhD, Jacob Haaber Christensen, MD PhD, Gunilla Enblad, MD PhD, Judit Mészáros Jørgensen, Karin E Smedby, MD PhD, Tarec Christoffer El-Galaly, MD PhD, Mats Jerkeman, MD PhD

Blood (2017) 130 (Supplement 1): 1560.

https://doi.org/10.1182/blood.V130.Suppl_1.1560.1560

Published: 2017

Journal Articles

Gender-Based Differences in Efficacy of Immuno-Chemotherapy for Diffuse Large B-Cell Lymphoma Revisited: A Danish Population-Based Study

Mette Dahl Bendtsen, MSc, Lasse Hjort Jakobsen, MSc, Judit Mészáros Jørgensen, Hans Erik Johnsen, MD Professor, Pär Lars Josefsson, MD, Christian Bjørn Poulsen, Jørn Starklint, MD, Gabriela Felicia Stein, MD, Per Trøllund Pedersen, MD, Jacob Haaber Christensen, MD PhD, Martin Bøgsted, Professor, Peter de Nully Brown, MD PhD, Tarec Christoffer El-Galaly, MD PhD

Blood (2017) 130 (Supplement 1): 1561.

https://doi.org/10.1182/blood.V130.Suppl_1.1561.1561

Published: 2017

Journal Articles

Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Adam Vilmar, PhD MD, Bente Arboe, Par Josefsson, MD PhD, Christian Poulsen, Jacob Haaber Christensen, Judit Jørgensen, MD PhD, Paw Jensen, Jørn Starklint, Per Troellund Pedersen, Michael Pedersen, Peter de Nully Brown, MD PhD

Blood (2016) 128 (22): 1781.

https://doi.org/10.1182/blood.V128.22.1781.1781

Published: 2016

Journal Articles

Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

Ida Bruun Kristensen, MD, Jacob Haaber, MD, PhD, Maria B Lyng, MSc, PhD, Lise Pedersen, Lars Melholt Rasmussen, Henrik J Ditzel, MD, PhD, Niels Abildgaard, MD

Blood (2012) 120 (21): 3977.

https://doi.org/10.1182/blood.V120.21.3977.3977

Published: 2012

Journal Articles

Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma.

Ida Bruun Kristensen, MD, Jacob Haaber, MD, PhD, Maria B Lyng, MSc, PhD, Lise Pedersen, Lars Melholt Rasmussen, Henrik J Ditzel, MD, PhD, Niels Abildgaard, MD

Blood (2012) 120 (21): 2922.

https://doi.org/10.1182/blood.V120.21.2922.2922

Published: 2012

Journal Articles

Multiple Myeloma Plasma Cell Expression of Hepatocyte Growth Factor mRNA Isoforms Correlates with Overall Survival In Myeloma Patients

Ida Bruun Kristensen, MD, Jacob Haaber Christensen, MD, PhD, Maria Lyng, MSc, PhD, Tobias W Klausen, MSc, Lene Meldgaard Knudsen, MD, PhD, Inger Marie S Dahl, Thomas Rasmussen, MSc, PhD, Henrik Ditzel, MD, PhD, Niels Abildgaard, MD, PhD

Blood (2010) 116 (21): 4983.

https://doi.org/10.1182/blood.V116.21.4983.4983

Published: 2010

NARROW

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Gender-Based Differences in Efficacy of Immuno-Chemotherapy for Diffuse Large B-Cell Lymphoma Revisited: A Danish Population-Based Study

Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma.

Multiple Myeloma Plasma Cell Expression of Hepatocyte Growth Factor mRNA Isoforms Correlates with Overall Survival In Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only